21 stories
Phase 3 is where the peptide pipeline actually monetizes. The trials that drive prescribing labels and payer coverage land here.
Recent and active Phase 3 programs covered on this site: SURMOUNT-5 (tirzepatide vs semaglutide), ACHIEVE-3 (orforglipron in obesity), TRIUMPH (retatrutide), REDEFINE-1 and -2 (CagriSema), SYNCHRONIZE-1 (Zealand's survodutide), REMODEL (semaglutide kidney), the SELECT cardiovascular outcomes trial, BriaCell's Bria-IMT in metastatic breast cancer, and AMPLIFY-201 (ELI-002 KRAS vaccine). Outside obesity and oncology, Boehringer Ingelheim, Crinetics, Verismo, and Lirum have active Phase 3 readouts in adjacent indications.
Stories here cover top-line readouts, full-data presentations at AACR, AAN, ESCMID, and AOSSM, and the FDA filings that follow.
Eli Lilly's triple-agonist retatrutide met all primary and key secondary endpoints in Phase III TRIUMPH-4. The 9mg and 12mg doses achieved significant weight loss and knee pain reduction at 68 weeks in patients with obesity and osteoarthritis. Seven more Phase III readouts expected in 2026.
Retatrutide met its primary endpoint of superior A1C reduction and all key secondary endpoints at 40 weeks compared with placebo in type 2 diabetes patients, also demonstrating significant weight loss.
Eli Lilly's triple GLP-1/GIP/glucagon receptor agonist retatrutide demonstrated up to 28.7% weight loss along with significant knee pain reductions in obesity patients with osteoarthritis. Seven additional Phase 3 trials expected to report throughout 2026.